Decoy Therapeutics is trading at $2.06, down 10.61%, with no clear catalyst established for the decline.
- On September 29, Decoy Therapeutics announced preclinical data showing a single intranasal dose maintained therapeutic drug levels in nasal and lung tissue for up to seven days; clinical trials are expected in 2027. The announcement did not attribute any stock-price move to the data.
- Major indices were lower, but none met the stated >0.5% threshold for emphasizing broad-market pressure.